Sign in

Alex Zhavoronkov

@elonverse.bsky.social
205 followers 3 following 46 posts

My only objective function is to extend productive longevity for everyone on the planet. Here to share research papers. x.com/biogerontology

PostsRepliesMedia
Alex Zhavoronkov @elonverse.bsky.social · 23/09/2026
Agentic AI closes the experimental loop - forming hypotheses, designing experiments, running analysis, revising from results. Our Cell perspective (Guo LY, Ting DSJ, Su X, Aliper A, Zhavoronkov A, Ting DSW): upside and risks are inseparable. www.cell.com/cell/abstrac...
021
Alex Zhavoronkov @elonverse.bsky.social · 23/09/2026
Co-Scientist, Robin, Biomni: agentic AI that forms hypotheses, runs experiments, and revises from results. New Cell perspective I co-authored on what this means, and why hallucination and accountability now matter more than capability. www.cell.com/cell/abstrac...
010
Alex Zhavoronkov @elonverse.bsky.social · 17/09/2026
A 9B model just beat GPT-5, Gemini 3.1, Grok, and Claude Opus at aging biology. Cover of Cell this week. LongevityBench: 17 tasks, 18 frontier LLMs. Scale didn't sort them - specialized training did. Models + benchmark public at longevitybenchmarks.org www.cell.com/cell/fulltex...
longevitybenchmarks.org
LongevityBench & Longevity-LLMs — AI for Aging Biology
The first comprehensive, multi-task, multi-omic benchmark for LLMs in aging biology. Five compact Longevity-LLMs from Insilico Medicine beat frontier models on aging tasks.
010
Alex Zhavoronkov @elonverse.bsky.social · 13/07/2026
Every MS/MS run detects thousands of unknowns. Existing AI requires the molecular formula first — an oracle that doesn’t exist for novel compounds. MARLIN: formula-free de novo structure elucidation. SOTA on NPLIB1 benchmark. arxiv.org/abs/2607.04774
000
Alex Zhavoronkov @elonverse.bsky.social · 13/07/2026
Day 71 #ScienceAIBench: Dopamine receptors D1-D4. GPT 5.5 wins 3/4 subtypes, peak Spearman 0.627 on D2. D4 hardest (max 0.228). Frontier captures dopamine SAR partly — subtype gaps remain. #DrugDiscovery #InsilicoBench
000
Alex Zhavoronkov @elonverse.bsky.social · 12/07/2026
DrugGen-2 makes molecule generation disease-aware: conditioning on disease ontology + target sequence, not only the protein (GPT-2 + GRPO RL). On diabetic nephropathy targets its ligands out-dock enalapril (-9.9 vs -8.3). Docking is a hypothesis, but the direction is right. arxiv.org/abs/2607.08404
000
Alex Zhavoronkov @elonverse.bsky.social · 12/07/2026
Day 70 #ScienceAIBench: antibody polyreactivity. GPT 5.5 leads (peak 0.152 Ovalbumin). Predicting nonspecific antibody binding stays a near-zero blind spot for every model. #DrugDiscovery #InsilicoBench
010
Alex Zhavoronkov @elonverse.bsky.social · 11/07/2026
Day 69 #ScienceAIBench: Lipophilicity & Solubility (ADMET). GPT 5.5 wins 4/4, peaking 0.925 on LogP. Kinetic Solubility hardest (max 0.314). LogP nearly solved; aqueous solubility still meaningfully harder. #DrugDiscovery #InsilicoBench
000
Alex Zhavoronkov @elonverse.bsky.social · 10/07/2026
Day 68 of #ScienceAIBench: subtype selectivity on opioid receptors (Delta/Kappa/Mu). GPT 5.5 wins all 3, peaking 0.639 on OPRD1; Gemini 3.1 Pro 2nd. Mu (OPRM1) stays hardest - no model clears 0.330. Grok 4.3 trails, dips negative.\n\n#DrugDiscovery #InsilicoBench
000
Alex Zhavoronkov @elonverse.bsky.social · 10/07/2026
Longevity medicine starts too late - aging trajectories may be set at or before birth. Our new Nature Health paper launches PROSPER, a life-course consortium taking gerodiagnostics from preconception to adulthood. www.nature.com/articles/s44...
011
Alex Zhavoronkov @elonverse.bsky.social · 09/07/2026
The enemy of every "AI scientist" is the context window. AstraZeneca's Ensemble QSP fixes it with 3-layer hierarchical memory: bounded context, 100% PD model selection vs 50-63% for Copilot, autonomous PK/PD. Memory > bigger model. arxiv.org/abs/2607.07666
000
Alex Zhavoronkov @elonverse.bsky.social · 09/07/2026
New PNAS paper on why exercise protects aging muscle: exercise -> FOXO -> suppresses DEAF1 -> normalizes overactive mTORC1. DEAF1 binds the mTOR promoter directly. Block FOXO and the benefit disappears. A druggable anti-sarcopenia axis. www.pnas.org/doi/10.1073/...
010
Alex Zhavoronkov @elonverse.bsky.social · 08/07/2026
MARLIN: de novo molecular structure from tandem mass spec with NO ground-truth formula - the oracle almost every rival method quietly assumes but that does not exist for novel compounds. SOTA on NPLIB1. arxiv.org/abs/2607.04774
000
Alex Zhavoronkov @elonverse.bsky.social · 08/07/2026
Most AI drug-discovery agents forget everything after each task and repay the full search cost. DrugSAGE gives them cross-task memory: verified skills + error->fix logs, reused. #1 of 9 SOTA agents on 33 tasks; big gains at near-zero test-time search. arxiv.org/abs/2605.15461
000
Alex Zhavoronkov @elonverse.bsky.social · 05/07/2026
The artery doesn't age as one tissue - it ages as a committee of cells that stop agreeing. New Aging Cell review (scRNA-seq): ECs, SMCs, fibroblasts + immune cells each reprogram toward inflammatory/senescent states. Annotation gaps = where AI multi-omics earns its keep. doi.org/10.1111/acel...
010
Alex Zhavoronkov @elonverse.bsky.social · 03/07/2026
BCIs are the future of humanity - and my academic publishing started there. In 2011 we published “Brain-Computer Interface Based on Generation of Visual Images” in PLOS ONE: decoding EEG as someone imagines a face vs a house, ~68% accuracy. Patent granted 2013. doi.org/10.1371/journal.pone.0020674
000
Alex Zhavoronkov @elonverse.bsky.social · 02/07/2026
New inflammaging mechanism (Nature Aging, Hao et al.): senescent cells export R-loops to the cytoplasm via DDX1/XPO1, firing cGAS-STING and the SASP. Blocking XPO1 with FDA-approved KPT-330 cut inflammaging and extended lifespan in aged mice. www.nature.com/articles/s43...
010
Alex Zhavoronkov @elonverse.bsky.social · 02/07/2026
At UBS Asian Investment Conference 2026 (Hong Kong), my message to investors on AI drug discovery: ignore the noise, look at the metrics. Insilico now has 13 IND approvals for AI drugs. sponsored.bloomberg.com/article/ubs/...
000
Alex Zhavoronkov @elonverse.bsky.social · 02/07/2026
Cryopreservation still runs on two cryoprotectants found by accident - glycerol (1949) and DMSO (1959). Our new Advanced Science Perspective: design the next generation like drugs. The bottleneck is open data, not hardware. doi.org/10.1002/advs...
010
Alex Zhavoronkov @elonverse.bsky.social · 29/06/2026
GEN covered Insilico Medicine's new collaboration with SK Biopharmaceuticals to discover AI-designed drug candidates for neuroimmune disorders of the CNS. Neuroimmunology is hard: safety, brain penetration, and translational biology all have to work. Now the real work begins.
011
Alex Zhavoronkov @elonverse.bsky.social · 12/06/2026
New review in Ageing Research Reviews: AI across the entire aging continuum - from hallmark-grounded biomarkers to Phase 2a trials. Happy to see many of our seminal longevity-AI papers cited. I configured my LongevityClaw to follow the authors' research. doi.org/10.1016/j.ar...
doi.org
Redirecting
000
Alex Zhavoronkov @elonverse.bsky.social · 12/06/2026
Our very important finding - NLRP3 in diabetic foot ulcers diabetesjournals.org/diabetes/art...
diabetesjournals.org
1155-OR: ISM5059, a Novel Peripherally Restricted NLRP3 Inhibitor, Accelerates Healing of Diabetic Foot Ulcers
Introduction and Objective: Diabetic foot ulcers (DFUs) are chronic, slow-healing wounds characterized by unresolved inflammation affecting a significant p
000
Alex Zhavoronkov @elonverse.bsky.social · 12/06/2026
The aging gut mapped at single-nucleus resolution in primates. NCoR1 decline drives barrier failure, inflammation, stem cell lineage shift. Metformin restores NCoR1 and delays intestinal aging in NHPs. Nature Aging 2026 doi.org/10.1038/s43587-026-01131-0
doi.org
Single-nucleus interrogation of primate small intestinal aging reveals NCoR1 decline as a conserved feature that is reversed by metformin - Nature Aging
Profiling the aging nonhuman primate small intestine at single-nucleus resolution, Li et al. identify barrier dysfunction, inflammation, stem cell fate bias and a decline in NCoR1 levels. Metformin tr...
010
Alex Zhavoronkov @elonverse.bsky.social · 11/06/2026
PKMYT1: from niche kinase to 5 clinical candidates in 4 years. Our patent review maps the inhibitor + degrader explosion (2021-2025). PoC via RP-6306 in CCNE1/FBXW7-altered cancers. doi.org/10.1080/13543776.2026.2674071
doi.org
Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025)
PKMYT1, a member of the WEE family of kinases that regulates mitotic entry by phosphorylating CDK1 at Thr14, has recently gained prominence as a promising synthetic lethal target for oncology. Sinc...
011
Alex Zhavoronkov @elonverse.bsky.social · 09/06/2026
Useful aging target-discovery paper: glucose-lowering drug target genes + tissue-specific eQTLs + DNA methylation + aging phenotypes. The authors prioritize 9 genes, with notable CNS signals. Good map for validation. link.springer.com/article/10.1...
link.springer.com
The tissue-specific effects of glucose-lowering drug targets on aging mediated through DNA methylation: a multi-omics genetic study - BMC Medicine
Background DNA methylation plays a key role in mediating the anti-aging effects of glucose-lowering drugs. This study aims to systematically explore the potential anti-aging effects of target genes of...
020
Alex Zhavoronkov @elonverse.bsky.social · 28/05/2026
Important preprint with Saudi Aramco: a Sanity Pipeline for AI-generated MOFs. Validated new materials are critical for direct air capture, carbon management, and sustainability technologies needed to decarbonize the world. chemrxiv.org/doi/full/10....
131
Reposted by Alex Zhavoronkov
Alán Aspuru-Guzik @aspuru.bsky.social · 21/01/2025
Thanks to @sebastian.bsky.social for the great interview for the @newquantumera.com We talked about #GQE and #VQE and #QML #quantummachinelearning #quantum #compchemsky
0207
Reposted by Alex Zhavoronkov
Akshat Nigam @akshatai.bsky.social · 22/01/2025
Excited to share our latest work, published this morning in Nature Biotechnology! 🎉 We developed a hybrid quantum computing-enhanced generative model to design KRAS inhibitors. Check it out here: rdcu.be/d68Fs. Some fascinating insights along the way:
33113
Reposted by Alex Zhavoronkov
ghazivakili.bsky.social @ghazivakili.bsky.social · 22/01/2025
Part 1: Exciting news! Our research on quantum drug discovery is now in Nature Biotechnology. A Quantum Computer helped design KRAS inhibitors, an elusive cancer target. These inhibitors were successfully synthesized and tested, marking a milestone in healthcare innovation. 🚀 #QuantumComputing #KRAS
1103
Alex Zhavoronkov @elonverse.bsky.social · 23/01/2025
Important paper in @naturebiotech.bsky.social www.nature.com/articles/s41...
nature.com
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors - Nature Biotechnology
A hybrid model combines quantum and classical approaches to generate compounds targeting the KRAS protein.
020
Reposted by Alex Zhavoronkov
Alán Aspuru-Guzik @aspuru.bsky.social · 22/01/2025
Glad to see our research on thr first #quantum + #ai application with experimental confirmation for #drugdiscovery out in Nature Biotechnology! @ghazivakili.bsky.social @elonverse.bsky.social Igor Stagljar @thematterlab.bsky.social
1205
Alex Zhavoronkov @elonverse.bsky.social · 17/01/2025
Another day, another paper -- and this research paper paves the way to a therapeutic program with very real therapeutic opportunity. Welcome our new paper with CUHK titled "Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis"
110
Alex Zhavoronkov @elonverse.bsky.social · 17/01/2025
And now, many of my friends with PRMT5 inhibitors in their pipelines will take notice. Welcome the new paper from University of Chicago Evgeny Izumchenko's group showing that PRMT5is can serve as powerful agents in adenoid cystic carcinoma of salivary glands.
111
Alex Zhavoronkov @elonverse.bsky.social · 17/01/2025
Huge congratulations to Dominika Wilczok on her first single author paper on generative AI for aging research. This paper has over 170 references and is a gargantuan amount of work. www.aging-us.com/article/2061...
021
Reposted by Alex Zhavoronkov
Zoe Corbyn @zoecorbyn.bsky.social · 10/01/2025
Inside the great AI drug race: www.bbc.com/news/article...
bbc.com
How AI uncovers new ways to tackle difficult diseases
Pharmaceutical firms are turning to AI to find new molecules that might be able to tackle disease.
032
Alex Zhavoronkov @elonverse.bsky.social · 05/01/2025
If you don't have quantitative benchmarks, you can not improve. Check out Domika Wilczok's paper on challenges in AI pharma R&D ascpt.onlinelibrary.wiley.com/doi/full/10....
ascpt.onlinelibrary.wiley.com
Progress, Pitfalls, and Impact of AI‐Driven Clinical Trials
Since the deep learning revolution of the early 2010s, significant efforts and billions of dollars have been invested in applying artificial intelligence (AI) to drug discovery and development (AIDD)....
031
Alex Zhavoronkov @elonverse.bsky.social · 05/01/2025
Don't forget to read about the best device to measure your skin over time in the context of your daily life. Thousands of meta clinical trials worldwide now. onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Skinly: A novel handheld IoT device for validating biophysical skin characteristics
Background Recent advancements in artificial intelligence have revolutionized dermatological diagnostics. These technologies, particularly machine learning (ML), including deep learning (DL), have s.....
010
Alex Zhavoronkov @elonverse.bsky.social · 15/12/2024
I noticed that @natureportfolio.bsky.social started tracking BlueSky in @altmetric.com @altmetric.bsky.social , so I decided to join. Check out our latest paper in @naturebiotech.bsky.social www.nature.com/articles/s41...
nature.com
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor - Nature Biotechnology
Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.
0133
Alex Zhavoronkov @elonverse.bsky.social · 15/12/2024
1/ 🚨 Breakthrough in IBD treatment! Insilico Medicine's AI-developed gut-restricted PHD inhibitor, ISM012-042, offers a novel solution for intestinal inflammation and mucosal barrier repair. 🚀 Read on for key findings from the latest @NatureBiotech study. 🧵
151
Alex Zhavoronkov @elonverse.bsky.social · 15/12/2024
The 12th ARDD will transpire 25-29th of August, 2025 - mark your calendars for the largest aging research biotechnology conference on the planet!
000